Great advances in science often come from outside the direct field of research. Since the early days of the epidemic, the HIV research community brought together clinicians, virologists, social scientists, and community members to try to shed light on the devastating disease. More than 30 years ...

There are a number of things that can impact our immune system’s ability to eliminate a virus; the expression levels of particular proteins—specifically interferon proteins—is one of them. In the past, human type I interferons (IFNs), a large subgroup of interferon proteins, were thought to ...

The January issue of the Journal includes papers on a range of topics and reports from two recent meetings – the Ghent HIV Reservoir Characterization Symposium and the Third Biennial Strategies for an HIV Cure Meeting. To read an overview of the issue, click here. The January ...

Last month’s announcement that the Bill and Melinda Gates Foundation will give up to $140 million to a Boston drug device manufacturer to develop an implantable mini-pump to deliver drugs for pre-exposure prophylaxis (PrEP) against HIV infection has focused attention on the future of PrEP. ...

Washington, DC – January 13, 2017 – A clever new tuberculosis vaccine has shown promise in trials in mice. If it succeeds, it will be the first new TB vaccine in a century. With the rise of multidrug resistant tuberculosis, the difficulty of curing the ...

Eight weeks of treatment with AbbVie’s investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for chronic hepatitis C achieved high SVR rates in genotype 1 Japanese patients. – 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR with 8 weeks of ...

A risk score based on routine assessments carried out during antenatal care in resource-limited settings can accurately predict which pregnant and breastfeeding women have an especially high risk of infection with HIV and would therefore benefit from pre-exposure prophylaxis (PrEP), investigators report in the online ...

Risk calculator developed by UCLA and Los Angeles LGBT Center may fill that void A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss ...

TreatmentUpdate is CATIE’s flagship digest on cutting-edge developments in HIV and hepatitis C research and treatment. TreatmentUpdate 218: Research with women and HIV, December 2016 issue is available at: http://www.catie.ca/en/treatmentupdate/treatmentupdate-218 Original Article

Antiviral therapy could be improved with the newly uncovered atomic-level details LA JOLLA—Salk Institute scientists have solved the atomic structure of a key piece of machinery that allows HIV to integrate into human host DNA and replicate in the body, which has eluded researchers for decades. ...

Smoking “dramatically” increases the risk of pregnancy loss – miscarriage or stillbirth – in HIV-positive women, US investigators report in the online edition of AIDS. Researchers from the large Women’s Interagency HIV Study (WIHS) examined the impact of smoking on pregnancy loss in HIV-positive and ...

CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced ...

The mini pump could be key to eradicating a scourge in Africa. You don't have to wait until after an infection to fight HIV. A technique known as pre-exposure prophylaxis has you taking preemptive medicine on a regular basis, greatly reducing the chances that HIV will ...

UCLA-led researchers suggest that blocking type I interferon may help combat the virus that causes AIDS In findings they call counterintuitive, a team of UCLA-led researchers suggests that blocking a protein, which is crucial to initiating the immune response against viral infections, may actually help combat ...

During the early (also known as acute) stage of HIV infection—about two weeks after initial exposure—the amount of virus produced in the body is very high. This occurs because the virus has overwhelmed and subverted the body’s defences. As acute infection is not associated with ...

ABIVAX reports new preclinical data supporting ABX464 as HIV functional cure and novel treatment for inflammatory diseases at HIV DART Meeting ABIVAX provides update on clinical development program for ABX464 for functional cure of patients with HIV-infection Original Article

Generic sofosbuvir-based combinations may not perform as well as therapy based on branded sofosbuvir-containing regimens, according to result of a study conducted in Qatar and presented to the recent 2016 AASLD Liver Meeting. People treated with generics were less likely to have a sustained virological ...

Four months of cognitive behavioral therapy for depression and antiretroviral adherence significantly improved adherence and depression scores when compared with treatment as usual in a three-way randomized trial involving adults with HIV infection. Relative improvements in adherence and depression held up in the eight months ...